News & Media: All

Jun 3, 2016

Philipson in Forbes: Give Tax Payers A Rebate for Medical Innovation?

In Tomas Philipson's latest Forbes.com commentary, he examines tax-funded R&D medical spending and the market value of that research.

Read the article here.

Jun, 2016

Precision's Renick In The Pink Sheet: Importance of Data

Will data be enough to support a new drug that battles COPD?  In a recent article in The Pink Sheet, Precision’s Dan Renick weighs in on the importance of data to understand the potential impact:

The Pink Sheet

May 30, 2016

Real World Superiority Data May Not Be Enough To Boost GSK's Breo I ...

Jun, 2016

Renick in The Pink Sheet: Showing Value at Launch for Competing Drugs

Precision’s Dan Renick comments in The Pink Sheet on the importance of showing value when there are competing drugs at the time of launch:

The Pink Sheet

May 30, 2016

GSK Leads Way With Real World Data, But Others Follow

By Emily Hayes

________________________________________

Executive S ...

Jun, 2016

Lakdawalla in AP's The Big Story: "Why Aren't You Shopping for Lower Prescription Drug Prices?"

Precision Health Economics founder and Chief Strategy Officer Darius Lakdawalla discusses the concept of shopping for the lowest prescription drug prices and "pharmacy apps" with Matthew Perrone of AP's The Big Story.

To read the article, please click here

May 31, 2016

PHE’s Goldman, Lakdawalla, and Philipson To Participate in BIO Panel

Precision Health Economics’ (PHE) Dana Goldman, Darius Lakdawalla, and Tomas Philipson will be featured in the BIO International Convention panel - The Future of Biosimilars: How Will Policy and Market Dynamics Impact Patient Value and Access in the US?

This panel will take place from 10:45a ...

May 20, 2016

Precision's Chandra and Shafrin Address Value Frameworks in JAMA

Precision Health Economics' Amitabh Chandra and Jason Shafrin, along with author Ravider Dhawan, examine the utility of cancer value frameworks in the latest edition of the Journal of the American Medical Association (JAMA).

To read the complete article, please click here.

May 20, 2016

Precision's Sharma in The Lancet: Liberating Data to Combat NCD's

Precision's Abhishek Sharma is a featured co-author in the latest version of The Lancet Diabetes & Endocrinology-- focusing on the challenges of collecting, analysing, and using data related to non-communicable diseases (NCD's).

To read the complete article, please click here.

May 17, 2016

Peter Neumann, Leader in Health Economics and Outcomes Research, Joins Precision Health Economics as Advisor

Los Angeles, May 17, 2016 -- Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.

Neumann is an internationally recognized thought leader and inn ...

May 12, 2016

Precision Researchers Prominently Featured in AJMC's Special Issue on HCV

Precision Health Economics authors are prominently featured in the May 2016, Special Issue on the Hepatitis C virus, released by The American Journal of Managed Care.

Four articles published in the journal feature PHE authors, including:

  • “Does Patient Cost Sharing for HCV Drug Make Sense ...

May 11, 2016

Precision To Have Strong Presence at ISPOR's 21st Annual International Meeting, Washington DC

Precision Health Economics (PHE) researchers and scientific advisors will once again have a very strong presence at ISPOR’s 21st Annual International Meeting in Washington DC from May 21-25, 2016. PHE experts will be teaching 2 short courses, moderating and speaking at 3 issue panels, present ...

May 9, 2016

Philipson in Forbes: "Speed and Safety at the FDA"

Tomas Philipson's latest Forbes.com Op-Ed examines generic drug approvals as well as speed and safety at the FDA.

To read the complete commentary, please click here.

Apr 13, 2016

Precision's Sharma in Boston Globe: Boston Drug Pricing Dozens of Times Higher Than Overseas

Precision's Abhishek Sharma is the lead author of a new study just published in The Journal of Pharmaceutical Policy and Practice (JPPP), recently cited in the Boston Globe's STAT Pharmalot Blog. The article highlights the findings of the study illustrating that drug prices in Boston are dozens ...

Apr 12, 2016

Precision at AMCP 2016!

Come visit the Precision Health Economics team and our Precision for Value colleagues at Booth 307 at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, to be held at the Moscone Convention Center, San Francisco, CA.

Look for examples of our expertise in the following presentations ...

Apr 6, 2016

Precision’s Eric Druyts to Speak at the 2016 International Liver Congress

Precision Health Economics’ Director Eric Druyts, PhD (candidate) will be attending the 2016 International Liver Congress in Barcelona, Spain, April 13 to 17 as an invited speaker presenting with the World Health Organization (WHO). Eric Druyts will be presenting on network meta-analysis as a ...

Apr 5, 2016

Tomas Philipson in Forbes: Value in Healthcare

In Tomas Philipson's latest Forbes.com op-ed, he and co-author Anupam B. Jena suggest it's time to stop scratching the surface when it comes to value in healthcare.

To read the complete commentary, please click here.

Mar 22, 2016

Precision for Medicine to Acquire ACT Oncology

Establishes leading platform for Precision Medicine Oncology Research

Bethesda, Md. and Flemington, N.J., March 22, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract res ...

Mar 17, 2016

Payer Reaction to FDA Safety Warnings- What Pharma Manufacturers Need to Know

Safety warnings on previously unknown adverse events can significantly impact a medication. Read Precision for Value's insights on what pharma manufacturers need to know:

http://www.pharmaceuticalonline.com/doc/payer-reaction-to-fda-safety-warnings-what=-pharma-manufacturers-need-to-know-0001

Mar 10, 2016

Precision's Goldman, Lakdawalla, and Philipson Challenge US Political Leaders in Wall Street Journal Open Letter

Earlier this week, Precision Health Economics founding partners Dana Goldman, Tomas Philipson and Darius Lakdawalla joined over 50 of their colleagues in an open letter published in the Wall Street Journal, challenging America's political leaders to pay more attention to the issue of chronic dis ...

Mar 4, 2016

Philipson Discusses Entitlement Reform in Forbes

In his latest Forbes.com Op-Ed, Tomas Philipson discusses entitlement reform: "Entitlement Reform: Will Cutting Medicare Raise Unfunded Liabilities In The Future?"

To read the complete article, please click here.

Feb 29, 2016

Precision at AMCP Partnership Forum

This week Precision for Value will be participating and speaking at the AMPC Partnership Forum, FDAMA 114: Improving the Exchange of Pharmacoeconomic Data which be held March 1-2, 2016 in Washington, D.C.

Feb 12, 2016

Dana Goldman's Work Cited in New York Times

Precision Health Economics co-founder Dana Goldman's work was recently cited in the New York Times: "Disparity in Life Spans of the Rich and the Poor Is Growing."

To read the complete article, please click here.

Feb 4, 2016

Precision's Lakdawalla on the BBC: 'You can't just ban Twinkies'

Precision's Darius Lakdawalla was recently interviewed for the BBC's Business Daily program, discussing the trend to ban large size sodas and other recent anti-junk food measures.

To play the interview, please click here.